AMG 701 Expanded Access Program
NCT05256446 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2024-09-23
Summary
Expanded access requests for AMG 701 may be considered for adult patients with relapsed and/or refractory multiple myeloma whose disease is in partial response or better after AMG 420 therapy. To request access, use Responsible Party contact information provided in this record.
Interventions
- DRUG
-
AMG 701
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
MD · Amgen
Eligibility
- Sex
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
NCT00179647 ·Status: COMPLETED ·Phase: PHASE3
-
An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma
NCT02568943 ·Status: NO_LONGER_AVAILABLE
-
Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease
NCT01410500 ·Status: APPROVED_FOR_MARKETING
-
Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma
NCT05908396 ·Status: TERMINATED ·Phase: PHASE1
-
agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma
NCT04754100 ·Status: COMPLETED ·Phase: PHASE1
-
Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release
NCT04771078 ·Status: AVAILABLE
-
Expanded Access for CC-4047
NCT03723096 ·Status: NO_LONGER_AVAILABLE
-
Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma
NCT06246162 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma
NCT02666209 ·Status: NO_LONGER_AVAILABLE
-
Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma
NCT02541643 ·Status: NO_LONGER_AVAILABLE
-
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
NCT07116616 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients
NCT00327249 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
NCT07266441 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib
NCT00706953 ·Status: WITHDRAWN ·Phase: PHASE2
-
Early Patient Access Treatment Use Protocol CA204-220
NCT02856438 ·Status: NO_LONGER_AVAILABLE
-
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
NCT03127761 ·Status: RECRUITING
-
Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma
NCT00440635 ·Status: COMPLETED
-
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
NCT06140524 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma
NCT04017130 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
NCT05646836 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse
NCT01087008 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma
NCT01302392 ·Status: COMPLETED ·Phase: PHASE3
-
Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma
NCT05757973 ·Status: APPROVED_FOR_MARKETING
-
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients
NCT00103662 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma
NCT04178902 ·Status: TERMINATED ·Phase: PHASE1